Displaying 1..1 of 1 -
per page
Order by
TAPESTRY PHARMACEUTICALS ANNOUNCES PLAN TO DISCONTINUE GENE EDITING OPERATIONS-Company to Focus on Lead Oncology Compounds-
More
Displaying 1..1 of 1 -
per page
Order by
Feb 2011 - 42 pages - $5,700
Sep 2010 - 25 pages - $2,000
Apr 2011 - 26 pages - $500
Jul 2011 - 39 pages - $5,700
Oct 2011 - 27 pages - $500
Apr 2011 - 78 pages - $3,500
May 2011 - 33 pages - $125
Feb 2011 - 29 pages - $125
Jan 2012 - 17 pages - $250
Dec 2010 - 28 pages - $125